Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.97% 7.45 7.20 7.70 7.60 7.45 7.60 154,860 12:32:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 20

Evgen Pharma Share Discussion Threads

Showing 8026 to 8044 of 8400 messages
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
DateSubjectAuthorDiscuss
04/4/2021
10:47
Diamond is the new Gnome eh? Suppose the thread would be boring without at least one idiot.
bumpa33
04/4/2021
10:41
mm - no not yet, over 80’s only and hospital staff, teachers etc. Probably be around 2023 by the time i get it.
bumpa33
03/4/2021
22:41
Quite so Money. Interesting look back there OT. An eye opener.
bocker01
03/4/2021
22:00
Anyways, if Prof Chalmers delivers negative news, then a drop of 37% would take the share price down to Evgen's £13m cash in the bank, and with so much potential material news that Huw could deliver thereafter, expected from the rest of the pipeline, then the share price should recover very quickly imho, and if Prof Chalmers delivers positive news, then the upside could be multiples of the current share price Gla :-)
moneymunch
03/4/2021
21:58
Indeed, SNG's phase 2 trial, consisting at that time of 100 patients.. Friday 17/7 shareprice was 35p with a market cap of £52m Monday 20/7 - positive results of trial announced. Reached a high of 239p (mcap £356m) and closed at 189p (£282m). So SNG market cap increased by no less than £300m on their phase 2 trial result on 100 patients.
on target
03/4/2021
21:52
Lol bocker, well if he hadn't got his lab assistant to close down the old thread, we could have continued the pointless bickering that he obviously revelled in, as is the case with most hypocrites who are the main protagonists and instigators because the only opinion that matters is his own, that's the usual way of anyone with a sanctimonious self-righteous know it all character, and the very reason why his lab assistant gave reason for closing down the the old thread...ha ha ha ha...you couldn't make it up...Gl :-)
moneymunch
03/4/2021
20:52
Not too sure about 50% down, otherwise that would take Evgen's Market Cap below the amount of cash they have in the bank c£13m....and i reckon if Prof Chalmers reports postive phase 2/3 efficacy data, then the share price will rise far higher than 50% imho....just remind me again on how high SNG's share price rose after encouraging phase 2 data ???
moneymunch
03/4/2021
20:41
The only one's with the answers here are those who have access to the clinical trial data such Prof Chalmers et al. ;-) ps Bumpa, have you had your jab yet in Spain? 43% of the UK have now been vaccinated and only 11% plus of the entire European population have had their's, and most countires there are now approaching 3rd lock down, whereas here in the UK numbers for infection and hospitalisation is at an all time low!!!??? I had the AZ jab, and proud to have it, i've got a Dutch mate who wouldn't touch it with a barge pole...30 people here have had the blood clot and unfortunetly 7 have died but that's from over 18m AZ jabs....yet 1 in 6 Covid patients run the risk of blood clots.....my holiday plans to France and Spain etc are on hold for the moment. ;-I
moneymunch
03/4/2021
20:33
I will ignore the last few posts from Bumpa! I am neutral on Evgen - I have no long or short positions. I am not into massive ramping like many other people here (or deramping either). Just sharing some honest thoughts on Evgen. I believe that Evgen made the right decision to start the trial in Dundee - because it is grant funded. However, forward risks are still high - could be a 50% up with positive interim analysis or 50% down with premature termination of the trial due to lack of efficacy.
diamondstar1
03/4/2021
20:29
No shortage of potential patients for SFX-01's Covid/ARDS trial it would semm ...Covid or not Covid!!! htTps://www.thoracic.org/patients/patient-resources/resources/top-pneumonia-facts.pdf Pneumonia is a form of acute respiratory infection that is most commonly caused by viruses or bacteria. It can cause mild to life-threatening illness in people of all ages, however it is the single largest infectious cause of death in children worldwide. Pneumonia killed more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. People at-risk for pneumonia also include adults over the age of 65 and people with preexisting health problems. The lungs are made up of small sacs called alveoli, which fill with air when a healthy person breathes. When an individual has pneumonia, the alveoli are filled with pus and fluid, which makes breathing painful and limits oxygen intake. These infections are generally spread by direct contact with infected people.
moneymunch
03/4/2021
20:24
Apologies, in no mood for idiots, can’t get that Socrates quote out of my head “I know that I’m intelligent because I know that I know nothing”...
bumpa33
03/4/2021
19:50
 0 There's a 28 day assessment on each patient following the 14 days of dosing, that's why the DSMB were able to assess the first 60 patients recruited to the trial, and prelimanary efficacy data will be available for the first 100 during Q2...Gl ;-) Background to the Trial 1 STAR-COVID 19 TRIAL TRAINING BACKGROUND AND OVERVIEW Community-acquired pneumonia is a leading cause of morbidity and mortality in the UK There have been no new therapies for managing pneumonia since advent of antibiotics in 1950s The global pandemic caused by novel coronavirus SARS-CoV-2, has highlighted the need for new drugs to treat pneumonia Development of anti-inflammatory therapies that prevent late stage complications is needed Such therapies are likely to be efficacious for a range of acute respiratory infections, including COVID-19 Patients with pneumonia and suspectedCOVID-19 are eligible for this trial. Patients do not require a positive COVID-19 test to be eligible .................... Background to the Trial 2 The nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is part of the human natural defence against inflammatory and oxidative stress such as the inflammation that occurs during a severe viral infection In animal studies, pharmacological activation of Nrf2 reduces the severity of acute respiratory distress syndrome (ARDS) SFX-01(stabilised sulforaphane), a drug developed by EvgenPharma, is an activator of Nrf2 SFX-01 has been tested in over 130 subjects in clinical trials and is well tolerated with main side effects being GI related and ameliorated by taking after food In this study one 300mg capsule of SFX-01 is taken orally per day for 14 days This is the first study of the effect of SFX-01 in humans with acute respiratory infections at risk of developing ARDS ....................... The trial will test the following hypothesis: Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection). ......................... Primary objective: To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia.Outcome measure:7 point ordinal scale measured on Day 15. Secondary Objectives: Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19 Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm Outcome measures: Cumulative incidence of serious Adverse events (SAEs) Discontinuation or temporary suspension of treatment .............................. Exploratory objectives (All sites) Biofire analysis of nasal swab or sputum sample Subanalysis of outcomes according to the causative pathogen Exploratory objectives (TAYSIDE ONLY) Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells Neutrophil functional studies in isolated cells Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood hTtps://star-covid19.com/
moneymunch
03/4/2021
19:23
Bumpa33.... you seem to be a cut and paste expert. Have you even managed a patient with ARDS or even designed a clinical trial?
diamondstar1
03/4/2021
19:23
What will they have then - a runny nose, headache perhaps? Trial aims: We think that SFX-01 may help people with pneumonia by reducing the amount of inflammation and damage in their lungs. We want to know if taking SFX-01 shortens your time in hospital. We also want to find out if you’re less likely to need oxygen for a long period or put on a ventilator and if you’re more likely to recover.
bumpa33
03/4/2021
19:18
The STAR trial is supposed to assess the impact on reducing severity or preventing the onset of ARDS. So, not all patients will have ARDS on inclusion into the study.
diamondstar1
03/4/2021
19:17
Here, try this for a start on ARDS httPs://en.wikipedia.org/wiki/Acute_respiratory_distress_syndrome#Causes Note the causes below, rather more than ‘just’ pathogens... Causes[edit] There are direct and indirect causes of ARDS depending whether the lungs are initially affected. Direct causes include pneumonia (including bacterial and viral), aspiration, inhalational lung injury, lung contusion, chest trauma, and near-drowning. Indirect causes include sepsis, shock, pancreatitis, trauma (e.g. fat embolism), cardiopulmonary bypass, TRALI, burns, increased intracranial pressure.[10] Fewer cases of ARDS are linked to large volumes of fluid used during post-trauma resuscitation.[11]
bumpa33
03/4/2021
18:59
If you can’t grasp the simple stuff, maybe stick to engine oil companies.
bumpa33
03/4/2021
18:58
You’re not preventing ARDS, you are treating and alleviating the symptoms of it ffs. And btw, It is not Neuroblastoma (which originates in the adrenal glands and usually affects young children), it is glioblastoma and glioma (which are brain cancers)
bumpa33
03/4/2021
18:52
Moneymunch - thanks for this valuable information. So, it’s a sink or float situation with the upcoming interim analysis. Yet, the patient population is potentially very heterogeneous - you may get some with background viral infections (eg COVID-19, influenza, etc) and bacterial pneumonias (staph, strep etc). Problem is Regulatory pathway is not clear to me- how do you get a drug approved for prevention of ARDS with various underlying pathogenic causes? I’m really not sure what FDA and EMEA will ask for - in terms of a pivotal Ph3 design.
diamondstar1
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210517 01:34:48